A clinical study of non-invasive diagnostic criteria for detrusor underactivity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1070230013

Enrollment

186

Registered

2023-04-30

Start date

2023-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

UAB syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Written consent was given for participation in the study. - Age at the time of informed consent is 18 years or older. - Willingness to adhere to the visit schedule and procedures specified in this study, and compliance is possible -Of the three voiding symptoms of UAB's syndrome as defined by ICS (hypovolemia, delayed voiding, abdominal pressure voiding), having any two or more symptoms for at least 12 weeks

Exclusion criteria

Exclusion criteria: -Researchers and others judged the participation of this study to be inappropriate.

Design outcomes

Primary

Measure	Time frame
Diagnostic predictive value based on noninvasive diagnostic criteria for DU.(%)	—

Secondary

Measure	Time frame
-PFS parameters (urine collection period) -PFS parameters (voiding phase) -Uroflowmetry parameters -Ultrasonographic PVR -BVE(%) -International Prostate Symptom Score -Major lower urinary tract symptom-score (CLSS). -ICIQ-UAB Score -Adverse events -BCI (men) and PIP1 (women) tabulation Summarized statistics of BCI (men) and PIP1 (women). -Urinary micro RNA analysis (only in collaborating laboratories where micro RNA analysis is feasible)	—

Measure

Time frame

-PFS parameters (urine collection period) -PFS parameters (voiding phase) -Uroflowmetry parameters -Ultrasonographic PVR -BVE(%) -International Prostate Symptom Score -Major lower urinary tract symptom-score (CLSS). -ICIQ-UAB Score -Adverse events -BCI (men) and PIP1 (women) tabulation Summarized statistics of BCI (men) and PIP1 (women). -Urinary micro RNA analysis (only in collaborating laboratories where micro RNA analysis is feasible)

—

Contacts

Public ContactKen Tsukamoto

Taiho Pharmaceutical Company

k-tsukamoto@taiho.co.jp+81-6-7176-5731

Outcome results